`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040
`
`
`
`Acid Salt Screen of L-224715 Free Base
`Created By: V.Vydra x-0307
`Notebook #: 72190-059
`Created for: M. Palucki
`Date: 18 Dec 2001
`
`F
`
`F
`
`F
`
`O
`
`NH2
`
`N
`
`N
`
`N
`
`N
`
`CF3
`
`
`
`L-224715
`
`Procedure:
`A 23 mg/ml stock solution of the substrate (L-224715 Free Base) was prepared by
`dissolving 525 mg of the L-224715 Free Base in 25ml of 1,2-Dichloroethane. Using the
`Cavro Liquid Handling Robot, 200 ul of this substrate stock solution was dispensed into
`each of the 96 wells (resulting in 4.6mg of substrate per well). Following the substrate
`dispense a 1:1 mole ratio of the acid stock solutions (0.03M) was then dispensed, by
`columns, to each of the 96 wells. The 96 well plate was placed in the Genevac to
`evaporate off the solvents. The plate was Genevaced at 1300rpm, at 35C for 6 hours
`(8mbar pressure). Once dry, the crystallization solvents were dispensed (by row) to the
`96 well plate. (200ul of crystallization solvent per well.) The Plate was capped and
`placed into a 70C oven for 1 hour to dissolve any solids. A temperature ramp from 70
`10 C over 8 hours was applied to the plate as crystallization conditions
`.
`
`Merck Exhibit 2132, Page 2
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040
`
`
`
`Results: X-Ray Powder Diffraction Results
`
`12--None
`
`FB
`
`11--p-Toluenesulfonic Acid
`
`10--Benzenesulfonic Acid
`
`9--Methanesulfonic Acid
`
`8--Lactic Acid
`
`7--Succinic Acid
`
`6--L-Tartaric Acid
`
`5--Sulfuric Acid
`
`1
`
`1
`1
`
`A
`
`2
`
`2
`2
`
`4
`4
`
`4
`4
`
`4
`4
`
`3
`
`3
`3 A
`
`4--Phosphoric Acid
`
`A
`
`A
`
`3--HCl
`
`2--Citric Acid
`
`1--Acetic Acid
`
`Columns--Bases:
`
`Solvents:
`Ethanol
`2-Propanol
`Toluene
`Nitromethane
`Acetonitrile
`1,2-DME
`Isopropyl Acetate
`MTBE
`
`FB =Free Base
`
`A = Amorphous
`
`Tf = Teflon
`
`# = New crystalline form
`
`Merck Exhibit 2132, Page 3
`Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
`IPR2020-00040
`
`